News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
February, 2025
February 2025
M T W T F S S
 12
3456789
10111213141516
17181920212223
2425262728  
Julien Mazières: Alectinib is the first ALK inhibitor to significantly improve DFS compared with CT
Photo taken from Julien Mazière/Twitter
Oct 23, 2023, 15:35

Julien Mazières: Alectinib is the first ALK inhibitor to significantly improve DFS compared with CT

Julien Mazières, Thoracic Oncology Specialist at Toulouse University Hospital, France, shared insights from the ALINA study from ESMO23 on X/Twitter:

“Another big hit ESMO 23. Alectinib is the first ALK inhibitor to significantly improve DFS compared with CT. Impressive curves and HR 0.24. Immediate practice-changing trial.”

Julien Mazières: Alectinib is the first ALK inhibitor to significantly improve DFS compared with CT

Source: Julien Mazières/Twitter.

alectinib ALINA study Benjamin J. Solomon cancer ESMO 2023 Julien Mazières OncoDaily Oncology Yi-Long Wu
Special Coverage
Blog
Feb 21, 2025, 15:06
The full press release of ELLOK is out
Blog
Feb 21, 2025, 14:59
Siobhan Freeney: What women in Ireland need to know about Dense Breasts and Cancer
Blog
Feb 21, 2025, 14:54
CEO of the Canadian Cancer Society about the inequities in cancer care across populations in Canada - UICC
Career
Feb 21, 2025, 14:34
Kristiyana Kaneva is appointed as Medical Director of Oncology Early Development at AbbVie
Blog
Feb 21, 2025, 14:27
Douglas Flora: A Cure for Cancer - Closer Than We Think?
Blog
Feb 21, 2025, 14:26
14th Biennial Childhood Leukemia and Lymphoma Symposium: Advancing Research and Collaboration in Budapest
Blog
Feb 21, 2025, 14:13
Rachel Chown: An incredibly inspiring and humbling talk from Liubov Lisovska
Science
Feb 21, 2025, 14:08
Survival improvement of patients with melanoma brain or leptomeningeal metastases in Denmark - CCIT-DK
Science
Feb 21, 2025, 13:51
Aaron Sverdlov: Identifying common pathways for doxorubicin and carfilzomib-induced cardiotoxicities
Blog
Feb 21, 2025, 13:40
Breaking barriers: ensuring equal cancer care access for diverse communities - SPCC
Blog
Feb 21, 2025, 13:29
Sana Al Sukhun: Enjoyed joining Emirates Oncology Society's SABCS
Blog
Feb 21, 2025, 13:28
Targeted protein degradation is changing the landscape of cancer treatment - The ICR